Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Nuvalent, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "SELECTED STATEMENTS OF OPERATIONS DATA 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 25,922 $ 13,558 $ 48,047 $ 26,251 General and administrative 8,140 5,175 16,225 10,170 Total operating expenses 34,062 18,733 64,272 36,421 Loss from operations Other income : Interest income and other income , net 4,972 267 9,990 406 Total other income, net 4,972 267 9,990 406 Net loss $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted average shares of common stock outstanding, basic and diluted 56,866,991 48,319,067 56,785,883 48,302,017 SELECTED BALANCE SHEET DATA June 30, December 31, 2023 2022 Cash, cash equivalents and marketable securities $ 431,239 $ 472,163 Working capital $ 416,197 $ 458,510 To..."
05/11/2023 8-K Quarterly results
Docs: "SELECTED STATEMENTS OF OPERATIONS DATA Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 22,125 $ 12,693 General and administrative 8,085 4,995 Total operating expenses 30,210 17,688 Loss from operations Other income : Interest income and other income, net 5,018 139 Total other income, net 5,018 139 Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted average shares of common stock outstanding, basic and diluted 56,703,873 48,284,778 SELECTED BALANCE SHEET DATA March 31, December 31, 2023 2022 Cash, cash equivalents and marketable securities $ 450,462 $ 472,163 Working capital $ 439,272 $ 458,510 Total assets $ 460,989 $ 482,459 Total liabilities $ 17,021 $ 19,481 Total stockholders’ equity $ 443,968 $ 46..."
08/10/2022 8-K Quarterly results
Docs: "Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results Preliminary dose escalation data expected in second half of 2022 from the ARROS-1study of NVL-520 for advanced ROS1 positive NSCLC and other solid tumors"
05/12/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results"
09/08/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy